Skip to content

US · XENE · BIOTECHNOLOGY

Xenon Pharmaceuticals Inc. (XENE) intrinsic value and stock valuation

$37.04as of 2026-11-21 · Mkt cap 6.22B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Xenon Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values XENE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XENE’s statements →

Xenon Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Burnaby, BC V5G 4W8 xenon-pharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$7.5M-25.3% 5y CAGRd
20112025
Net income
-$-345.91M
20112025
Free cash flow
-$-279.92M
20112025
Total equity
$581.8M+27.7% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$7.5M$0.00$0.00$9.43M$18.4M
Operating income-$-373.07M-$-279.3M-$-214.05M-$-129.14M-$-78.99M
Net income-$-345.91M-$-234.33M-$-182.39M-$-125.37M-$-78.88M
EPSd-$-4.36M-$-3.01M-$-2.73M-$-2.07M-$-1.81M
Operating cash flow-$-279.12M-$-181.39M-$-145.33M-$-98.43M-$-69.5M
Capital expenditure-$-800K-$-3.08M-$-5.62M-$-2.89M-$-2.05M
Free cash flow-$-279.92M-$-184.46M-$-150.94M-$-101.32M-$-71.55M
Total assets$981.7M$798.1M$964.8M$754.2M$572M
Total debt$7.94M$9.02M$10.9M$10.4M$8.26M
Net debt-$-191.22M-$-133.7M-$-137.74M-$-46.81M-$-167.43M
Total equity$581.8M$754.9M$927.9M$721.5M$550M
Cash and short-term investments$548.9M$626.9M$638.1M$592.1M$551.8M
Income statement
20252024202320222021
Revenue$7.5M$0.00$0.00$9.43M$18.4M
Cost of revenue$2.54M$2.56M$167.5M$0.00$0.00
Gross profit$4.96M-$-2.56M-$-167.51M$9.43M$18.4M
Research and development expenses$300.9M$210.4M$167.5M$105.8M$75.5M
Selling, general and administrative expenses$79.6M$68.9M$46.5M$32.8M$22M
Other expenses-$-2.54M-$-2.56M-$-167.51M$0.00$0.00
Operating expenses$378M$276.7M$46.5M$138.6M$97.4M
Cost and expenses$380.6M$279.3M$214.1M$138.6M$97.4M
Interest income$26.8M$41.9M$27.6M$8.71M$470K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.54M$2.56M$3.54M$1.41M$910K
Ebitda-$-342.35M-$-235.86M-$-210.51M-$-127.74M-$-78.09M
Operating income-$-373.07M-$-279.3M-$-214.05M-$-129.14M-$-78.99M
Total other income/expenses, net$28.2M$40.9M$31.4M$3.89M$100K
Income before tax-$-344.89M-$-238.42M-$-182.69M-$-125.25M-$-78.89M
Income tax expense$1.02M-$-4.09M-$-290K$120K-$-10K
Net income-$-345.91M-$-234.33M-$-182.39M-$-125.37M-$-78.88M
Weighted average shares outstanding$79.3M$77.9M$66.9M$60.5M$43.6M
Weighted average diluted shares outstanding$79.3M$77.9M$66.9M$60.5M$43.6M
Balance sheet
20252024202320222021
Cash and short-term investments$548.9M$626.9M$638.1M$592.1M$551.8M
Net receivables$1.37M$1.47M$870K$990K$2.77M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$560.7M$635.3M$645M$600.3M$559M
Property, plant and equipment, net$15.4M$18.2M$18.9M$16.9M$12.5M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$37.2M$127.5M$292.8M$128.7M$0.00
Total non-current assets$421M$162.9M$319.8M$153.9M$13M
Total assets$981.7M$798.1M$964.8M$754.2M$572M
Accounts payable$3.88M$5.07M$8.6M$8.49M$3.82M
Short-term debt$1.53M$1.37M$1.3M$490K$600K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$41.8M$35.6M$27.3M$22.7M$14.3M
Long-term debt$6.41M$7.65M$9.6M$9.95M$7.65M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$358.1M$7.65M$9.6M$9.95M$7.65M
Capital lease obligations$6.41M$9.02M$10.9M$10.4M$8.26M
Total liabilities$399.9M$43.2M$36.9M$32.7M$22M
Common stock$1.6B$1.46B$1.44B$1.07B$783.2M
Retained earnings-$-1.25B-$-899.47M-$-665.14M-$-482.75M-$-357.37M
Accumulated other comprehensive income (loss)$340K-$-1.61M-$-80K-$-3M-$-990K
Total equity$581.8M$754.9M$927.9M$721.5M$550M
Total investments$386.9M$611.7M$782.2M$663.5M$376.1M
Total debt$7.94M$9.02M$10.9M$10.4M$8.26M
Net debt-$-191.22M-$-133.7M-$-137.74M-$-46.81M-$-167.43M
Cash flow statement
20252024202320222021
Net income-$-345.91M-$-234.33M-$-182.39M-$-125.37M-$-78.88M
Depreciation and amortization$2.54M$2.56M$3.54M$1.62M$910K
Stock-based compensation$53.7M$50.7M$32.4M$20.4M$10M
Change in working capital$4.36M$5.71M$5.63M-$-680K-$-2.65M
Accounts receivable$100K-$-610K$130K$1.76M-$-460K
Inventory$0.00$0.00$0.00$0.00-$-2.97M
Accounts payable$5.51M$8.53M$3.93M$8.06M$2.97M
Net cash provided by operating activities-$-279.12M-$-181.39M-$-145.33M-$-98.43M-$-69.5M
Investments in property, plant and equipment-$-800K-$-3.08M-$-5.62M-$-2.89M-$-2.05M
Acquisitions, net$0.00$0.00$0.00$296M-$-144.75M
Net cash used for investing activities$218M$165M-$-117.17M-$-296M-$-246.77M
Common stock issued$117.1M$12.1M$353.5M$277.8M$447.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$117.1M$12.1M$353.5M$278.5M$447.5M
Net change in cash$56.5M-$-5.93M$91.4M-$-118.45M$130.7M
Cash at end of period$199.2M$142.7M$148.6M$57.2M$175.7M
Operating cash flow-$-279.12M-$-181.39M-$-145.33M-$-98.43M-$-69.5M
Capital expenditure-$-800K-$-3.08M-$-5.62M-$-2.89M-$-2.05M
Free cash flow-$-279.92M-$-184.46M-$-150.94M-$-101.32M-$-71.55M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Xenon Pharmaceuticals Inc.

        Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.

        CEO
        Ian C. Mortimer
        Employees
        316
        Beta
        0.61

        Explore

        Frequently asked questions

        What is the intrinsic value of Xenon Pharmaceuticals Inc. (XENE)?

        InvestorsCraft does not currently publish an intrinsic value for XENE. How the IC value is calculated.

        Is XENE undervalued?

        InvestorsCraft does not publish an undervaluation signal for XENE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.